bpc-157 crohn's disease JPP No 5/2013 article 09 BPC-157 & Crohn's... the gut

This inherent stability means it is somewhat more robust than larger, more complex peptides under handling conditions

Mean weight change was approximately -2.0 kg for AOD-9604 (twice-daily) versus -1.5 kg placebo (p = not significant)

Individual results may vary, and some practices may be unsuitable or unsafe for certain individuals

Potential interactions include: Metformin (used for type 2 diabetes) Proton pump inhibitors (PPIs) and H2-receptor antagonists (used for acid reflux) Colchicine (used for gout) Nitrous oxide (anaesthetic gas that can inactivate B12) Chloramphenicol (may reduce the haematological response to B12 therapy) If you take any of these medications long-term, discuss B12 monitoring with your healthcare provider